% | $
Quotes you view appear here for quick access.

Pharmacyclics, Inc. Message Board

  • effenberg effenberg Apr 23, 2013 3:08 PM Flag


    Overvalued? The future carries much more weight than the past in valuing any stock, but especially biotechs. In light of the numbers, I don't think these billion-dollar biotechs are overvalued at all. In fact, I think they're both still undervalued considering their potential.
    Since Pharmacyclics and Sarepta have yet to receive approval for their lead drugs, we do need to consider the possibility that bumps along the road could occur. However, both companies seem to have the odds in their favor at this point. - insider monkey

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • they have revenue indication for 5 billion...that should be a market cap of 40-60 billion

      • 2 Replies to geterginto
      • "they have revenue indication for 5 billion...that should be a market cap of 40-60 billion"

        I will sell you all of mine based on $10 billion...right now. You can keep all of the upside from there, Big Shooter.


      • well, there is more in the pipeline as we all know. If other things take off, specially auto immune, this company will surely grow into a major biotech. Ibrutinib's outstanding performance will be more and more recognized now and If you read between all messages and releases you can guess that things will get to the market much earlier than expected. For sure, this months short return to 70 was a "gift "as Truth said.

        IMO, this was the very last chance to get in cheap. This will get back now to where it was and might even reach new highs soon. As we said beginning of 2013, this will be an exiting year guys

        Sentiment: Strong Buy

257.100.00(0.00%)Apr 23 3:59 PMEDT